Status:
COMPLETED
A Study to Evaluate Safety and Tolerability After Oral Dosing of AZD1656 in Healthy Volunteers
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Eligibility:
MALE
20-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess safety and tolerability of AZD1656 after single ascending oral doses in healthy male subjects
Eligibility Criteria
Inclusion
- Provision of informed consent
- Clinically normal physical findings and laboratory values as judged by the investigator including negative test of Hepatitis B surface antigen, antibodies to HIV virus and antibodies to hepatitis C virus.
Exclusion
- Clinically significant illness or clinically relevant trauma, as judged by the investigator, within 2 weeks before the first administration of the Investigational Product
- History of psychiatric or somatic disease/condition that may interfere with the objectives of the study, as judged by the investigator
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2008
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00726427
Start Date
July 1 2008
End Date
September 1 2008
Last Update
December 3 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Philadelphia, Pennsylvania, United States